Pandemic highlights broken contract processes: Office of Contracting may be the fix
In collaboration with KPMG Law, World Commerce & Contracting (WorldCC) surveyed executives from across the globe, gathering insights into the process of contracting across industries ― and how to fix perennial and costly problems in the contract development process.
- Almost 90% of organizations have ineffective and fragmented contracting processes
- 76% of organizations want to prioritize digitalization of contracts
- A potential solution lies in setting up an “Office of Contracting”
The COVID-19 pandemic has highlighted a significant problem with contracts, as revealed by a report released by World Commerce & Contracting (WorldCC) and KPMG Law, entitled Can the contracting process improve without an owner?
For decades, organizations have tried to simplify the contract process―testing and implementing contract management tools and systems, but to little effect. Now, as digitalization gathers pace, streamlining the contract process is a major priority. As the report makes clear, this issue is not isolated to one business or industry type. It is a global problem that is slowing organizations down.
“Contracts directly impact the health and wealth of every organization. Yet, for all their importance, on average, contracts suffer more than 9% value erosion,” says Jason McQuillen, a partner in KPMG Law in Australia, head of its Legal Operations Transformation business and report co-author. “They only gain executive attention when things go wrong, and the focus is on who to blame. The dominant, widely acknowledged reason for this is simple: no one owns the contract delivery process.”
Only 10.8% of organizations consider their end-to-end contracting process to be “very effective.” As one research respondent commented, “Getting a contract is like having a root canal.” Cost was also an area of contention among respondents, with the least efficient processes reportedly averaging more than US$10,000 per contract, simply for reviewing and processing activities.
Tim Cummins, WorldCC President and report co-author, comments: “Contracting has never been addressed effectively. The report highlights a clear frustration with departments involved in the contracting process, lengthy cycle times, and CEOs believe they are losing money.”
Focus on digitalization
Digitalization of the contracting process is now a priority for 76% of respondents, yet only 26% of respondents believe that their technology team is well equipped to support their digitalization initiative. Digitalization alone cannot fix the broader issues.
“I’m optimistic that the impact of the pandemic will encourage organizations to change things, and digitalizing contracting is now a business priority,” says Nicola Brooks, Director for KPMG Law in the UK, head of its Legal Operations Transformation business and report co-author. “But most organizations will not succeed by focusing on this in isolation. Rather, to succeed, organizations need to have an operating model as part of this.”
What’s the solution?
The report concludes that sustained progress and improving the quality of the contracting process depends on achieving a single point of process ownership and accountability. WorldCC and KPMG Law say that introducing an ‘Office of Contracting’ within each organization is the solution to tackling a fragmented and costly process. The OOC would be a small group responsible for all contracts across the enterprise and the process surrounding it. They would work in harmony with the multiple functions, coordinating and coalescing.
Stuart Fuller, Global Head of Legal Services at KPMG, concludes: “The WorldCC and KPMG Law report shows that there is a clear problem in the contracting process. The solution needs clear ownership within the organization, and external support from trusted advisers with real, global experience in this critical area for business, who can drive value creation and end the value erosion.”
About the research:
The report is based on input received from a series of round-table discussions and an on-line survey conducted by World Commerce & Contracting in the period from January to March 2021.
More than 40 executives participated in the roundtables and shared their views on the key trends in commercial and contract management. This was supplemented by input from more than 300 survey respondents, together representing a range of industry and geographic perspectives and size of organization. While taking account of all responses, the report focuses primarily on the 200 organizations with annual revenues of more than US$500 million since the complexities being examined are strongly related to the size of the business.
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 146 countries and territories and in FY20 had close to 227,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients. More: home.kpmg.
About World Commerce & Contracting
World Commerce & Contracting is a not for profit association and the only global body promoting standards and raising capabilities in commercial practice.
The organization works to inspire individuals and organizations through research and ideas and equips its members with knowledge and networks that support successful contracts and commercial relationships. More: worldcc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005212/en/
Contact information
Amy Diaz
KPMG International
(416) 777-3042
amydiaz@kpmg.ca
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
